HyreCar - HYRE Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HyreCar in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HYRE shares.
View HYRE analyst ratings or view top-rated stocks.

1 analysts have issued 1-year target prices for HyreCar's shares. Their HYRE share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.67 in the next year. This suggests a possible upside of 902.9% from the stock's current price.
View analysts price targets for HYRE or view top-rated stocks among Wall Street analysts.

HyreCar's stock was trading at $4.71 at the beginning of the year. Since then, HYRE shares have decreased by 88.0% and is now trading at $0.5650.
View the best growth stocks for 2022 here.

HyreCar saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,400,000 shares, an increase of 12.9% from the October 31st total of 1,240,000 shares. Based on an average daily trading volume, of 2,510,000 shares, the days-to-cover ratio is presently 0.6 days.
View HyreCar's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our HYRE earnings forecast.

HyreCar Inc. (NASDAQ:HYRE) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.05. The business earned $9.65 million during the quarter, compared to the consensus estimate of $9.70 million. HyreCar had a negative trailing twelve-month return on equity of 1,016.64% and a negative net margin of 46.03%. During the same period last year, the company earned ($0.10) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other HyreCar investors own include Ampio Pharmaceuticals (AMPE), Arbutus Biopharma (ABUS), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Interpace Biosciences (IDXG), OPKO Health (OPK), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

(HYRE) raised $12 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 2,500,000 shares at a price of $5.00 per share. Network 1 Financial Securities served as the underwriter for the IPO.

HyreCar trades on the NASDAQ under the ticker symbol "HYRE."

HyreCar's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.32%), State Street Corp (1.28%), P.A.W. Capital Corp (0.73%), White Pine Capital LLC (0.29%), Renaissance Technologies LLC (0.15%) and Royce & Associates LP (0.13%). Insiders that own company stock include Arctis Global Llc, Bock Serge De, Brian Allan, Grace Mellis, Henry Park, Jayaprakash Vijayan, Joseph Furnari, Michael Furnari and Robert Scott Brogi.
View institutional ownership trends.

Shares of HYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HYRE stock can currently be purchased for approximately $0.57.

HyreCar (NASDAQ:HYRE) has a market capitalization of $12.41 million and generates $35.72 million in revenue each year. The company earns $-25,950,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

HyreCar's mailing address is 355 SOUTH GRAND AVENUE SUITE 1650, LOS ANGELES CA, 90071. The official website for the company is www.hyrecar.com. The company can be reached via phone at (888) 688-6769 or via email at j.evans@hyrecar.com.